查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1274336

患者來源的異種移植模型全球市場研究報告-2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Patient-Derived Xenograft Model Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 154 Pages | 商品交期: 最快1-2個工作天內

價格

全球對患者來源的異種移植模型市場的需求將從2022年的3.3102億美元增長到2030年的36.3467億美元，預計2023-2030年調查期間的複合年增長率為34.92%。

近年來，患者來源的異種移植 (PDX) 模型備受關注。 這些模型的一般特徵是將源自患者的腫瘤組織引入新鮮的免疫功能低下的小鼠中。 該模型用於臨床前研究，以尋找治療效果和治療耐藥性的生物標誌物，並追蹤腫瘤生長對治療的反應。 PDX 模型越來越被廣泛認為是了解癌症特徵、設計新治療方法和預測治療效果的有用工具。

市場動態：

推動患者來源的異種移植 (PDX) 模型市場擴張的主要原因之一是全球範圍內對定制治療的需求不斷增長。 對個性化治療的需求不斷增長、公共和私人對癌症研究的持續支持以及製藥行業加大研發力度是推動該市場擴張的主要因素。 為改進當前療法而加大的研發力度正在進一步影響市場。 公共和商業部門對癌症研究的持續財政和經濟支持將推動市場擴張。 然而，定制 PDX 模型的成本和使用動物模型進行癌症研究的嚴格規定可能會阻礙市場的發展。

這份研究報告描述了波特的五力模型、市場吸引力分析和價值鏈分析。 這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。 此外，這些工具還能夠全面評估全球患者來源的異種移植模型市場的各個細分市場。 患者來源的異種移植模型行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

患者來源的異種移植模型市場報告的這一部分提供了國家和地區層面的細分市場的詳細數據，從而幫助戰略制定者確定目標受眾和他們各自產品或服務的即將到來的機會。以支持

按腫瘤類型

  • 肺癌
  • 胰腺癌
  • 前列腺癌
  • 乳腺癌
  • 其他癌症

按模型類型

  • 鼠標
  • 大鼠

由最終用戶

  • 製藥和生物製藥公司
  • 學術和研究機構
  • CRO□CDMO

按地區分析：

本節介紹了區域前景，重點關注北美、歐洲、亞太地區、拉丁美洲、中東和非洲患者來源的異種移植模型市場的當前和未來需求。 此外，該報告重點關注所有主要地區每個單獨應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。 患者來源的異種移植模型市場的主要參與者是 Charles River Laboratories、The Jackson Laboratory、Crown Bioscience、Altogen Labs、Envigo、WuXi AppTec、Oncodesign、Hera Biolabs、XenTech、Abnova Corp。戰略發展，例如能力、合作夥伴關係、財務概覽、協作、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。 我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

  • 本報告的內容
    • 目的
    • 目標受眾
    • 獨特的銷售主張 (USP) 及其提供的內容
  • 調查範圍
  • 調查方法
    • 市場調研過程
    • 市場研究方法

第 2 章執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章患者來源的異種移植模型 - 行業分析

  • 簡介 - 市場動態
  • 市場驅動因素
  • 市場製約因素
  • 市場機會
  • 行業趨勢
  • 波特的五力分析
  • 市場吸引力分析
    • 按腫瘤類型進行的市場吸引力分析
    • 按模型類型進行市場吸引力分析
    • 按市場進行的吸引力分析：按最終用戶
    • 市場吸引力分析：按地區

第四章價值鏈分析

  • 價值鏈分析
  • 原材料分析
    • 成分錶
    • 原材料製造商列表
    • 主要原材料價格走勢
  • 潛在買家名單
  • 營銷渠道
    • 直接營銷
    • 間接營銷
    • 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章患者來源異種移植模型的全球市場分析（按腫瘤類型）

  • 腫瘤類型概述
  • 實際數據和預測數據
  • 按腫瘤類型分析
  • 肺癌
  • 胰腺癌
  • 前列腺癌
  • 乳腺癌
  • 其他癌症

第 7 章患者來源異種移植模型的全球市場分析：按模型類型分類

  • 按模型類型概述
  • 實際數據和預測數據
  • 按模型類型分析
  • 鼠標
  • 大鼠

第 8 章患者來源異種移植模型的全球市場銷售分析：按最終用戶分類

  • 最終用戶總結
  • 實際數據和預測數據
  • 最終用戶分析
  • 製藥和生物製藥公司
  • 學術和研究機構
  • CRO□CDMO

第 9 章患者來源異種移植模型的全球市場銷售分析：按地區

  • 按地區進行的銷售前景分析
  • 介紹銷售分析
  • 北美銷售分析
    • 概覽、歷史和預測銷售分析
    • 北美各部門的銷售分析
    • 北美銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史和預測銷售分析
    • 按細分市場進行的歐洲銷售分析
    • 按國家/地區劃分的歐洲銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 意大利銷售分析
    • 俄羅斯銷售分析
    • 其他歐洲銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史和未來銷售分析
    • 亞太地區各部門的銷售分析
    • 亞太國家/地區銷售分析
    • 在中國的銷售分析
    • 印度銷售分析
    • 日本的銷售分析
    • 韓國銷售分析
    • 澳大利亞銷售分析
    • 其他亞太地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史和未來銷售分析
    • 拉丁美洲各部門的銷售分析
    • 拉丁美洲國家/地區的銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利的銷售分析
    • 其他拉丁美洲銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史和未來銷售分析
    • 中東/非洲地區的銷售分析
    • 中東和非洲國家/地區的銷售分析
    • 沙特阿拉伯銷售分析
    • 阿聯酋銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 其他中東和非洲銷售分析

第10章患者來源異種移植模型公司的競爭狀況

  • 人源異種移植模型市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第11章公司簡介

  • 前 10 名公司的市場份額分析
  • 市場集中度
  • 查爾斯河實驗室
    • 公司簡介
    • 企業收入
    • 產品介紹
    • 近期發展狀況
  • 傑克遜實驗室
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 中冠生物科學
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 阿爾托金實驗室
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 恩維戈
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 藥明康德
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 腫瘤設計
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • 赫拉生物實驗室
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • XenTech
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期發展狀況
  • Abnova 公司
    • 公司簡介
    • 企業收入
    • 產品信息
    • 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

Product Code: VMR112110348

The global demand for Patient-Derived Xenograft Model Market is presumed to reach the market size of nearly USD 3634.67 MN by 2030 from USD 331.02 MN in 2022 with a CAGR of 34.92% under the study period 2023 - 2030.

Patient-derived Xenograft (PDX) models have gained attention in recent years. These models are typically characterized by introducing fresh immunodeficient mice with patient-derived tumour tissues. These models have been successfully utilized in preclinical investigations to find potential biomarkers for treatment response and resistance and to track tumours' growth in response to therapy. PDX models are becoming more widely acknowledged as a useful tool for determining the characteristics of cancer, coming up with new treatments, and foretelling the efficacy of therapies. 

Market Dynamics:

One of the key reasons promoting the expansion of the patient-derived xenograft (PDX) model market is the rising need for customized therapy on a global scale. The increasing need for personalized treatment, ongoing public and private support for cancer research, and an increase in R&D efforts in the pharmaceutical industry are the main factors propelling the expansion of this market. The increase in R&D efforts to improve the current treatment alternatives further impacts the market. Market expansion is accelerated by ongoing financial and economic assistance from the public and commercial sectors for cancer research. However, the cost of the customized PDX models and the strict regulations for utilizing animal models in cancer research may obstruct the market. 

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of patient-derived xenograft model. The growth and trends of patient-derived xenograft model industry provide a holistic approach to this study. 

Market Segmentation:

This section of the patient-derived xenograft model market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities. 

By Tumor Type

  • Lung Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Breast Cancer
  • Other Cancer

By Model Type

  • Mice
  • Rats

By End-User

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic & Research Institutes
  • CROs & CDMOs

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Patient-Derived Xenograft Model market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the patient-derived xenograft model market include Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo, WuXi AppTec, Oncodesign, Hera Biolabs, XenTech, Abnova Corp. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . PATIENT-DERIVED XENOGRAFT MODEL - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Tumor Type
    • 3.7.2 Market Attractiveness Analysis By Model Type
    • 3.7.3 Market Attractiveness Analysis By End-user
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET ANALYSIS BY TUMOR TYPE

  • 6.1 Overview by Tumor Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Tumor Type
  • 6.4 Lung Cancer Historic and Forecast Sales by Regions
  • 6.5 Pancreatic Cancer Historic and Forecast Sales by Regions
  • 6.6 Prostate Cancer Historic and Forecast Sales by Regions
  • 6.7 Breast Cancer Historic and Forecast Sales by Regions
  • 6.8 Other Cancer Historic and Forecast Sales by Regions

7 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET ANALYSIS BY MODEL TYPE

  • 7.1 Overview by Model Type
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Model Type
  • 7.4 Mice Historic and Forecast Sales by Regions
  • 7.5 Rats Historic and Forecast Sales by Regions

8 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET SALES ANALYSIS BY END-USER

  • 8.1 Overview by End-user
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-user
  • 8.4 Pharmaceutical And Biopharmaceutical Companies Historic and Forecast Sales by Regions
  • 8.5 Academic & Research Institutes Historic and Forecast Sales by Regions
  • 8.6 CROs & CDMOs Historic and Forecast Sales by Regions

9 . GLOBAL PATIENT-DERIVED XENOGRAFT MODEL MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE PATIENT-DERIVED XENOGRAFT MODEL COMPANIES

  • 10.1. Patient-Derived Xenograft Model Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF PATIENT-DERIVED XENOGRAFT MODEL INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Charles River Laboratories
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. The Jackson Laboratory
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. Crown Bioscience
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Altogen Labs
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. Envigo
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. WuXi AppTec
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Oncodesign
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Hera Biolabs
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. XenTech
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Abnova Corp.
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Tumor Type (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Other Cancer Market Sales by Geography (USD MN)
  • Analysis Market by Model Type (USD MN)
  • Mice Market Sales by Geography (USD MN)
  • Rats Market Sales by Geography (USD MN)
  • Analysis by End-user (USD MN)
  • Pharmaceutical And Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Research Institutes Market Sales by Geography (USD MN)
  • CROs & CDMOs Market Sales by Geography (USD MN)
  • Global Patient-Derived Xenograft Model Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Patient-Derived Xenograft Model Report
  • Market Research Process
  • Market Research Methodology
  • Global Patient-Derived Xenograft Model Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Tumor Type
  • Market Attractiveness Analysis by Model Type
  • Market Attractiveness Analysis by End-user
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Tumor Type (USD MN)
  • Lung Cancer Market Sales by Geography (USD MN)
  • Pancreatic Cancer Market Sales by Geography (USD MN)
  • Prostate Cancer Market Sales by Geography (USD MN)
  • Breast Cancer Market Sales by Geography (USD MN)
  • Other Cancer Market Sales by Geography (USD MN)
  • Global Market Analysis by Model Type (USD MN)
  • Mice Market Sales by Geography (USD MN)
  • Rats Market Sales by Geography (USD MN)
  • Global Market Analysis by End-user (USD MN)
  • Pharmaceutical And Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Academic & Research Institutes Market Sales by Geography (USD MN)
  • CROs & CDMOs Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.